Submit a Revision

*your email :**
page name* : such as "Introduction", "Conclusion"..etc
<table border="0" cellspacing="5" cellpadding="0"><tbody><tr><td colspan="6"> <p> <strong>Observed APOBEC3-induced mutations at recognized HIV-1 RT resistance sites<sup>a</sup></strong> </p> </td> </tr><tr><td align="center"><strong>HIV-1 RT Resistance Position</strong><br></td> <td align="center"><strong>Wildtype Codon</strong><br></td> <td align="center"><strong>APOBEC3G Target</strong><br></td> <td align="center"><strong>APOBEC3F Target</strong><br></td> <td align="center"><strong>Observed Mutant Codon</strong><br></td> <td align="center"><strong>Mutant Frequency</strong><br></td> </tr><tr><td colspan="6"> <hr></td> </tr><tr><td align="center"><strong>M41 [NRTI]</strong><br></td> <td align="center">ATG(G)<br></td> <td align="center">+<br></td> <td align="center">-<br></td> <td align="center">ATA<br></td> <td align="center">0.7<br></td> </tr><tr><td align="center"><strong>D67 [NRTI]</strong><br></td> <td align="center">GAC<br></td> <td align="center">-<br></td> <td align="center">+<br></td> <td align="center">na<br></td> <td align="center">0<br></td> </tr><tr><td align="center"><strong>Q151 [NRTI]</strong><br></td> <td align="center">CAG(G)<br></td> <td align="center">+<br></td> <td align="center">-<br></td> <td align="center">CAA×<br></td> <td align="center">0.5<br></td> </tr><tr><td align="center"><strong>M184 [NRTI]</strong><br></td> <td align="center">ATG(G)<br></td> <td align="center">+<br></td> <td align="center">-<br></td> <td align="center">ATA<br></td> <td align="center">0.6<br></td> </tr><tr><td align="center"><strong>L210 [NRTI]</strong><br></td> <td align="center">TTG(A)<br></td> <td align="center">-<br></td> <td align="center">+<br></td> <td align="center">TTA×<br></td> <td align="center">0.1<br></td> </tr><tr><td align="center"><strong>E138 [NNRTI]</strong><br></td> <td align="center">GAG(A)<br></td> <td align="center">-<br></td> <td align="center">+<br></td> <td align="center">AAG<br></td> <td align="center">0.3<br></td> </tr><tr><td align="center"><strong>G190 [NNRTI]</strong><br></td> <td align="center">GGA<br></td> <td align="center">+<br></td> <td align="center">+<br></td> <td align="center">AGA<br></td> <td align="center">0.5<br></td> </tr><tr><td align="center"><strong>M230 [NNRTI]</strong><br></td> <td align="center">ATG(G)<br></td> <td align="center">+<br></td> <td align="center">-<br></td> <td align="center">ATA<br></td> <td align="center">0.7<br></td> </tr><tr><td colspan="6"> <hr></td> </tr><tr><td colspan="6"> <p> <sup>a</sup>All available hypermutant HIV-1 subtype B reverse transcriptase sequences in the Los Alamos HIV Sequence Database [40] were analyzed (1 sequence sampled per individual, 10 total). Listed resistance positions are potential targets of APOBEC3G and/or APOBEC3F. Class of antiretroviral resistance listed in brackets (NRTI = nucleoside RT inhibitor, NNRTI = non-nucleoside RT inhibitor) [51]. Nucleotides in parentheses are immediately downstream of codons involved in antiretroviral resistance, and are included in the APOBEC3 dinucleotide target motifs. x = synonymous (silent) mutation, * = canonical resistance codon. </p> </td> </tr></tbody></table>
Confirmation code: Enter the code exactly as it appears. All letters are case insensitive, there is no zero.